{"id":4284,"date":"2026-10-12T08:32:32","date_gmt":"2026-10-12T08:32:32","guid":{"rendered":"https:\/\/nhdbio.com\/?p=4284"},"modified":"2026-10-12T08:32:32","modified_gmt":"2026-10-12T08:32:32","slug":"cagrisema-redefinir9-dose-faible-68-semaines","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/fr\/cagrisema-redefine9-low-dose-68-weeks\/","title":{"rendered":"CagriSema \u00e0 faible dose : comprendre la perte de poids de 21% \u00e0 68 semaines"},"content":{"rendered":"
\n
\"Illustration
Editorial illustration, not an experimental photograph.<\/figcaption><\/figure>\n

What is worth noting this time is not just the number of 21%, but that the lower-dose combination also produced an effect. The answer given by REDEFINE 9 still needs to be viewed in the context of the trial population, comparator, and analysis method.<\/p>\n

\n

This article looks only at REDEFINE 9<\/h2>\n

The announcement dated September 21 mentioned two trials at the same time. REDEFINE 9 studied adults with overweight or obesity, comparing CagriSema with placebo, and observed for 68 weeks; the other trial, REIMAGINE 5, studied type 2 diabetes and used tirzepatide as the comparator.<\/p>\n

The populations and comparators of the two trials are different. What is discussed here is REDEFINE 9, and its 21% cannot be directly treated as the gap between two drugs when compared with the 9.1% from another trial.<\/p>\n<\/section>\n

\n

21% and 2%, how should the difference be calculated?<\/h2>\n

The announcement reported that the 1.0 milligram\/1.0 milligram combination group had an average weight loss of 21.0%, while the placebo group had 2.0%, using the efficacy estimand. Subtracting the two gives 19 percentage points.[1]<\/a><\/p>\n

Assuming both groups started at 100 kilograms, 21% and 2% correspond to reductions of 21 kilograms and 2 kilograms, respectively. This is a hypothetical example to help understand percentages, not the participants' actual starting weight, and it does not mean every person reached the average.<\/p>\n